All Oncology News

Patient Toxicity and QOL Concerns Must Be Considered in Breast Cancer Treatment Decision-Making

February 19th 2024

Following chemoradiation, maintenance osimertinib improved PFS vs placebo in patients with stage III EGFR-mutant non–small cell lung cancer.

Jane L. Meisel, MD, of Emory University School of Medicine

Reflex Molecular Testing May Enhance Targeted Therapy Benefit in Early-Stage Lung Cancer

February 19th 2024

Jane L. Meisel, MD, discusses the importance of prioritizing patients’ toxicity concerns and quality of life in the management of breast cancer.

Jobelle Baldonado, MD, of Moffitt Cancer Center

Bispecific Antibodies and Noncovalent BTK Inhibitors Expand Horizons in DLBCL and MCL

February 19th 2024

Jobelle Baldonado, MD, highlights the emergence of targeted therapies and the need for reflex-ordered molecular testing in early-stage lung cancer.

Catherine C. Coombs, MD, of University of California Irvine School of Medicine

Hematologists and Patients Come Together for Patient-Focused GVHD Discussions

February 18th 2024

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.

Carrie L. Kitco, MD, Vanderbilt University Medical Center

FDA Approves Osimertinib Plus Chemo for EGFR-Mutated NSCLC

February 17th 2024

Carrie L. Kitko, MD, and Sagar S. Patel, MD, discuss recent treatment developments and ongoing unmet needs in the graft-vs-host treatment paradigm.

The FDA has approved osimertinib (Tagrisso) plus platinum-based chemotherapy for use in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Kristi Rosa

FDA Approves Lifileucel for Unresectable or Metastatic Melanoma

The FDA has approved osimertinib (Tagrisso) plus chemotherapy for use in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.

The FDA has approved lifileucel (Amtagvi) for the treatment of adult patients with unresectable or metastatic melanoma that previously has been treated with other therapies.

Kristi Rosa

Enfortumab Vedotin Plus Pembrolizumab Receives Priority Review in Japan for First-Line Urothelial Carcinoma

The FDA has approved lifileucel suspension (Amtagvi) for adult patients with unresectable or metastatic melanoma following prior treatment with a PD-1 inhibitor, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor.

Ahsan Arozullah, MD, MPH, senior vice president and head of Oncology Development at Astellas

FDA Grants Orphan Drug Designation to Tigilanol Tiglate in Soft Tissue Sarcoma

The sNDA for enfortumab vedotin-ejfv plus pembrolizumab in patients with metastatic urothelial cancer has received priority review in Japan.

Kyle Doherty

RWJBarnabas Health and Rutgers Cancer Institute of New Jersey First in State Offering Novel Form of Liver Cancer Treatment

The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of patients with soft tissue sarcoma.

Rutgers Cancer Institute

Jagsi Holds a Magnifying Glass to Radiation Oncology: Uncovering Key Disparities and When to Omit Radiation in Breast Cancer

Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health will offer hepatic artery infusion therapy for patients with liver tumors.

Reshma Jagsi, MD, DPhil, of Winship Cancer Institute

Megan Hollasch

Active Surveillance Is a Safe and Acceptable Treatment Alternative in Select D-TGCT

Investigating when radiation therapy can be appropriately omitted and striving to uncover disparities are areas of focus in the field of radiation oncology.

R. Lor Randall, MD, David Linn Endowed Chair for Orthopaedic Surgery, professor, chair, the Department of Orthopaedic Surgery, The University of California, Davis

FDA Approves AI-Powered Detection Device for Skin Cancers

R. Lor Randall, MD, discusses the adequacy of active surveillance for select patients with diffuse-type tenosynovial giant cell tumor.

Insights Into Pediatric Oncology on Childhood Cancer Day: Advances, Challenges, and Survivorship

The FDA has granted clearance for the first real-time, non-invasive skin cancer evaluation system .

Burton Eliot Appel, MD, of Hackensack University Medical Center and Jersey Shore University Medical Center

FDA Approves Tepotinib for Metastatic NSCLC Harboring MET Exon 14 Skipping Alterations

Burton Eliot Appel, MD, discusses the landscape of pediatric oncology on International Childhood Cancer Day.

The FDA has granted approval to tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.

Kristi Rosa

Real-World Analysis Sheds Light on Brain Metastases Incidence in HER2+ Breast Cancer

The FDA has granted approval to tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.

Sarah Sammons, MD, associate director, the Metastatic Breast Cancer Program, Dana-Farber Cancer Institute

Breaking Boundaries: Advancements and Challenges in Treatment with ADCs in NSCLC

Sarah Sammons, MD, discusses what is known about the incidence of brain metastases in patients with breast cancer.

Joshua K. Sabari, MD, of NYU Langone Health

Enfortumab Vedotin/Pembrolizumab Signals Shift in Urothelial Carcinoma Treatment Paradigm

Joshua K. Sabari, MD, discusses updates in ADCs in NSCLC.

Matthew Galsky, MD, professor, medicine, director, genitourinary medical oncology, co-director, the Center of Excellence for Bladder Cancer, associate director, translational research, the Tisch Cancer Institute, Mount Sinai

Florida Cancer Specialists & Research Institute Welcomes Gynecologic Oncologist Bradley Monk, MD, FACOG, FACS To Lead Late-Phase Clinical Research Program

Matthew Galsky, MD, discusses the significance of the FDA approval of enfortumab vedotin plus pembrolizumab as a first-line regimen in urothelial cancer.

Florida Cancer Specialists & Research Institute

Roivant Sciences to Discontinue RVT-2001 Development in Myelodysplastic Syndrome

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Bradley Monk, MD, FACOG, FACS has joined the statewide practice.

Matt Gline, chief executive officer of Roivant

Caroline Seymour

Are Higher Standards for Expedited FDA Approvals Needed?

Investigation of RVT-2001 will be discontinued following an insufficient display of benefit in patients with myelodysplastic syndrome.

Sanket Dhruva, MD, MHS, assistant professor, medicine, the University of California San Francisco

Megan Hollasch

Updates to MDS Classification Complicate Yet Better Inform Treatment Navigation in MDS

Many clinicians have reported a lack of understanding of the FDA approval process and a desire for strong premarket evidence to support these approvals.

Mikkael A. Sekeres, MD, MS, of Sylvester Comprehensive Cancer Center

BLA Resubmitted to FDA for Denileukin Diftitox in Relapsed/Refractory Cutaneous T-cell Lymphoma

Mikkael A. Sekeres, MD, MS, discusses the influence of therapeutic developments and conflicting classification systems on the management of MDS.

$The BLA seeking the approval of denileukin diftitox in patients with relapsed/refractory cutaneous T-cell lymphoma was resubmitted to the FDA.$

Kyle Doherty

Unlocking the Potential: The Evolution of ADCs in HER2+ NSCLC

The BLA seeking the approval of denileukin diftitox in patients with relapsed/refractory cutaneous T-cell lymphoma was resubmitted to the FDA.

ONC201 Looks to Prove Efficacy in Trial For Rare H3K27M-Mutated Diffuse Midline Gliomas

Joshua K. Sabari, MD, explains the utility of ADCs in patients with NSCLC and their benefit in patients with EGFR-, ALK-, or HER2-mutant disease.

Stephen Bagley, MD, MSCE, assistant professor, medicine, section chief, Neuro-Oncology, the Hospital of the University of Pennsylvania, Abramson Cancer Center

Megan Hollasch

The Ongoing Investigation of GLSI-100 Continues in the Flamingo-01 Study for HER2/Neu+ Breast Cancer

The dopamine receptor D2 antagonist ONC201 is under evaluation in patients with H3K27M-mutated diffuse midline glioma in the phase 3 ACTION trial.

Breast Cancer | Image Credit: © SciePro - stock.adobe.com

Kyle Doherty

FDA Grants Priority Review to Repotrectinib for NTRK+ Solid Tumors

The ongoing Flamingo-01 trial continues to investigate GLSI-100 in HER2/neu-positive breast cancer following various holds.

Extending the Frontiers of Checkpoint Inhibition in Merkel Cell Carcinoma

Repotrectinib is under priority review for patients with NTRK-positive locally advanced or metastatic solid tumors and high unmet medical need.

Ann W. Silk, MD, MS, codirector, the Merkel Cell Carcinoma Center of Excellence, physician, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School

Ann W. Silk, MD, MS;James A. DeCaprio, MD

Recent Approvals Across Hematologic Malignancies Usher in a New Era

In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.

Mikkael A. Sekeres, MD, MS, of University of Miami Health System and Sylvester Comprehensive Cancer Center

Standard-of-Care Drugs Provide Strong Foundation For Effective Combinations in Hematologic Malignancies

Mikkael A. Sekeres, MD, MS, highlights recent approvals and emerging therapeutics in hematologic malignancies discussed by his colleagues.

Catherine C. Coombs, MD, of the University of California Irvine School of Medicine